Record mula sa primary source

pembrolizumab · NCT06295731 update sa rehistro

katayuan: ACTIVE_NOT_RECRUITING → RECRUITING; primary_completion: 2029-05 → 2029-12; completion: 2029-05 → 2031-05; enrollment: 410 → 450; primary_outcomes: ['Phase 2: Objective Response Rate (ORR)', 'Phase 3: Progression-Free Survival (PFS)', 'Phase 3: Overall Survival (OS)'] → ['Phase 2: Objective Response Rate by investigator (ORRinv)', 'Phase 3: Progression-Free Survival by Investigator (PFSinv)', 'Phase 3: Overall Survival (OS)']; mga bansa: {'total_sites': 87, 'us_sites': 25} → {'total_sites': 89, 'us_sites': 26}